[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112012004284B8 - ácidos biliares poli-hidroxilados para tratamento de transtornos biliares - Google Patents

ácidos biliares poli-hidroxilados para tratamento de transtornos biliares

Info

Publication number
BR112012004284B8
BR112012004284B8 BR112012004284A BR112012004284A BR112012004284B8 BR 112012004284 B8 BR112012004284 B8 BR 112012004284B8 BR 112012004284 A BR112012004284 A BR 112012004284A BR 112012004284 A BR112012004284 A BR 112012004284A BR 112012004284 B8 BR112012004284 B8 BR 112012004284B8
Authority
BR
Brazil
Prior art keywords
bile
polyhydroxylated
disorders
treatment
bile acids
Prior art date
Application number
BR112012004284A
Other languages
English (en)
Other versions
BR112012004284A2 (pt
BR112012004284B1 (pt
Inventor
Ahab Sheps Jonathan
Wang Renxue
Ling Victor
Original Assignee
Ahab Sheps Jonathan
Qing Bile Therapeutics Inc
Wang Renxue
Ling Victor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ahab Sheps Jonathan, Qing Bile Therapeutics Inc, Wang Renxue, Ling Victor filed Critical Ahab Sheps Jonathan
Publication of BR112012004284A2 publication Critical patent/BR112012004284A2/pt
Publication of BR112012004284B1 publication Critical patent/BR112012004284B1/pt
Publication of BR112012004284B8 publication Critical patent/BR112012004284B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ácidos biliares poli-hidroxilados para tratamento de transtornos biliares. a invenção proporciona, em parte, ácidos biliares poli-hidroxilados para tratamento de distúrbios biliares, por exemplo, distúrbios biliares resultantes de colestase ou hipertansão portal. a invenção também proporciona, em parte, ácidos biliares poli-hidroxilados para estímulo do fluxo de bílis. novos compostos ácido 2a, 3a, 7a, 12(alfa)-tetra-hidroxi-5(beta)-colanóico e ácido 3(alfa), 4a, 7a, 12(alfa)-tetra-hidroxi-5(beta)-colanóico são divulgados, usos dos mesmos e síntese dos mesmos.
BR112012004284A 2009-08-25 2010-08-25 ácidos biliares poli-hidroxilados para tratamento de transtornos biliares BR112012004284B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23675009P 2009-08-25 2009-08-25
US61/236,750 2009-08-25
PCT/CA2010/001338 WO2011022838A1 (en) 2009-08-25 2010-08-25 Polyhydroxylated bile acids for treatment of biliary disorders

Publications (3)

Publication Number Publication Date
BR112012004284A2 BR112012004284A2 (pt) 2017-06-13
BR112012004284B1 BR112012004284B1 (pt) 2021-01-05
BR112012004284B8 true BR112012004284B8 (pt) 2021-05-25

Family

ID=43627124

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012004284A BR112012004284B8 (pt) 2009-08-25 2010-08-25 ácidos biliares poli-hidroxilados para tratamento de transtornos biliares

Country Status (7)

Country Link
EP (1) EP2470553B1 (pt)
JP (1) JP5909774B2 (pt)
CN (1) CN102712672B (pt)
AU (1) AU2010286253A1 (pt)
BR (1) BR112012004284B8 (pt)
SG (1) SG178562A1 (pt)
WO (1) WO2011022838A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2758060T (pt) 2011-09-19 2018-01-24 ETH Zürich Moduladores de ror gama para o tratamento de complicações de diabetes ii
EA201891154A1 (ru) 2011-10-28 2019-02-28 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
NZ734451A (en) 2012-06-19 2018-12-21 Intercept Pharmaceuticals Inc Preparation, uses and solid forms of obeticholic acid
CN104853758A (zh) * 2012-11-28 2015-08-19 英特赛普特医药品公司 肺部疾病的治疗
EP2781217A1 (en) * 2013-03-18 2014-09-24 ETH Zurich ROR gamma modulators
EP3027637B1 (en) * 2013-08-01 2019-10-09 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services The glycine conjugate of beta-muricholic acid as an inhibitor of the farnesoid x receptor for the treatment of obesity, insulin resistance or non-alcoholic fatty liver disease
CN104523703A (zh) * 2014-12-24 2015-04-22 聂飚 一种游离脂肪酸转运蛋白小分子抑制物的应用
KR102204406B1 (ko) * 2019-01-23 2021-01-18 (주)샤페론 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 염증성 장질환 예방 또는 치료용 조성물
CN109762043B (zh) * 2019-03-06 2020-07-24 华南理工大学 鹅去氧胆酸及其制备方法
CN116925168A (zh) * 2019-08-23 2023-10-24 深圳云合医药科技合伙企业(有限合伙) 胆汁酸衍生物及其组合物和应用
CN110548037B (zh) * 2019-09-24 2023-06-02 江西天元药业有限公司 精制熊胆粉及其增强体质治疗和预防肿瘤和癌症的用途
CN113024624B (zh) * 2019-12-25 2024-09-10 上海科胜药物研发有限公司 一种去氧胆酸的合成方法
WO2022233398A1 (en) 2021-05-04 2022-11-10 Kostner Pharma Gmbh COMPOUNDS FOR REDUCING LIPOPROTEIN(a)
CN115337312A (zh) * 2022-08-19 2022-11-15 金熊药业(珠海横琴)有限公司 胆酸复合物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS632932A (ja) * 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
ATE292956T1 (de) * 1998-07-24 2005-04-15 Seo Hong Yoo Klare wässrige lösungen enthaltend gallensäuren
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US20090074895A1 (en) * 2005-05-02 2009-03-19 Vanadis Bioscience Ltd Composition and uses thereof
US20090232913A1 (en) * 2005-05-02 2009-09-17 Momir Mikov Composition for the Control of Cholesterol Levels
CA2716922C (en) * 2008-02-26 2016-06-28 British Columbia Cancer Agency Branch Polyhydroxylated bile acids for treatment of biliary disorders

Also Published As

Publication number Publication date
BR112012004284A2 (pt) 2017-06-13
EP2470553C0 (en) 2024-06-19
WO2011022838A1 (en) 2011-03-03
BR112012004284B1 (pt) 2021-01-05
WO2011022838A8 (en) 2011-06-16
EP2470553B1 (en) 2024-06-19
EP2470553A4 (en) 2013-02-20
SG178562A1 (en) 2012-03-29
AU2010286253A1 (en) 2012-04-19
CN102712672B (zh) 2016-09-14
JP2013502442A (ja) 2013-01-24
JP5909774B2 (ja) 2016-04-27
EP2470553A1 (en) 2012-07-04
CN102712672A (zh) 2012-10-03

Similar Documents

Publication Publication Date Title
BR112012004284B8 (pt) ácidos biliares poli-hidroxilados para tratamento de transtornos biliares
CY1114872T1 (el) Συνθεσεις και μεθοδοι χρησης αντισωματων εναντι της σκληροστεϊνης
ECSP099414A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteína quinasa
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
UA99882C2 (uk) Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти)
DE602007005120D1 (de) 2-pyridonderivate zur behandlung von krankheiten oder leiden, bei denen eine inhibierung der aktivität der neutrophilen elastase von nutzen ist
IL196543A (en) Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
NI200700296A (es) Imidazoquinolinas como inhibidores de cinasa de lipido
BRPI0612112A8 (pt) composto, composição farmacêutica, e, método de tratar doenças ou condições mediadas por ccr1.
NO20091700L (no) Florizinanaloger som inhibitorer av glukose-ko-transporter 2
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
CL2009001151A1 (es) Compuestos derivados de acidos carbociclicos aliciclicos de benzomorfanos, procedimiento de preparacion, composicion farmaceutica, utiles para tratar enfermedades influenciadas por la inhibicion de la enzima 11beta-hidroxiesteroide deshidrogenasa, como trastornos metabolicos.
ATE528002T1 (de) Pyridoncarboxamidderivate zur behandlung hyperproliferativer und angiogenese-vermittelter leiden
CR20110103A (es) Heteroarilos sustituidos
NO20092444L (no) Heteroarylamidderivater
TW200806325A (en) Therapeutic uses of inhibitors of RTP801
SG10201407403UA (en) Treatments For Gastrointestinal Disorders
CL2007002578A1 (es) Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer.
WO2010148065A3 (en) Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
CY1118966T1 (el) Νεες συνθεσεις για την προληψη και/ή την θεραπεια εκφυλιστικων διαταραχων του κεντρικου νευρικου συστηματος
MX2009003981A (es) Agentes moduladores del receptor de calcio.
MX2011010918A (es) Metodo para el tratamiento de trastornos asociados con la actividad de la cinasa de proteina ck2.
MX2009001315A (es) Compuestos de dimetilciclobutilo substituidos, su preparación y uso en medicamentos.
WO2009037542A3 (en) Spirocyclic compounds as stearoyl coa desaturase inhibitors

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25G Requested change of headquarter approved

Owner name: RENXUE WANG (CA) , VICTOR LING (CA) , JONATHAN AHA

B25C Requirement related to requested transfer of rights

Owner name: RENXUE WANG (CA) , VICTOR LING (CA) , JONATHAN AHA

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: QING BILE THERAPEUTICS INC. (CA)

Free format text: ANULADA A PUBLICACAO CODIGO 25.3 NA RPI NO 2458 DE 14/02/2018 POR TER SIDO INDEVIDA.

Owner name: QING BILE THERAPEUTICS INC. (CA)

B25A Requested transfer of rights approved

Owner name: QING BILE THERAPEUTICS INC. (CA)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/08/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF